Lumos Pharma Inc expected to post a loss of $1.07 a share - Earnings Preview

Lumos Pharma

02/11/2021 02:09

* Lumos Pharma Inc  LUMO.OQ   LUMO.O  is expected to show a fall
in quarterly revenue when it reports  results on November 3. 
​* Refinitiv's mean analyst estimate for Lumos Pharma Inc is for
a loss of $1.07 per share. For the same quarter last year, the
company reported earnings of 21 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Lumos Pharma
Inc is $26.5​, about 64.1% above​ its last closing price
of $9.52. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 302021   -1.05       -1.03      -1.04     Missed  -0.6
 Mar. 312021   -0.88       -0.87      -1.04     Missed  -19
 Dec. 312020   -0.86       -0.86      -0.31     Beat    64​
 Sep. 302020   -0.66       -0.64      0.21      Beat    132.6
 ​​Jun.        -0.72       -0.71      -0.65     Beat    8.9
 302020                                                 
 Mar. 312020   -0.83       -0.82      -0.14     Beat    83​
 Dec. 312019   -2.52       -2.52      -1.98     Beat    21.4
 Sep. 302019   -2.43       -2.43      -2.43     Met     0
 This summary was machine generated November 2 at 02:09 GMT.  All
figures in US dollars unless otherwise stated